---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-25-000095"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2025-12-02T23:59:59+00:00"
generated_at: "2026-05-16T15:45:27.282416+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Autolus appoints former BioNTech CSO Ryan Richardson to Board

## Summary
- Ryan Richardson appointed as Class I director effective Dec 1, 2025; served as BioNTech CSO (2018–2025).
- Will receive £33,000 annual retainer and initial option grant for 80,000 ADSs at $1.41/ADS, vesting over 36 months.
- Richardson led BioNTech's corporate strategy, capital markets, and multiple M&A deals.
- Prior roles include Executive Director at J.P. Morgan Healthcare Investment Banking (2011–2018).

## SEC filing metadata
- accession: 0001730463-25-000095
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2025-12-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000095/0001730463-25-000095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000095/autl-20251201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-25-000095
- JSON: https://secwatch.observer/filing/0001730463-25-000095.json
- Plain text: https://secwatch.observer/filing/0001730463-25-000095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.